Relyea Zuckerberg Hanson LLC bought a new stake in Johnson & Johnson (NYSE:JNJ) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 7,735 shares of the company’s stock, valued at approximately $1,128,000. Johnson & Johnson accounts for approximately 1.1% of Relyea Zuckerberg Hanson LLC’s portfolio, making the stock its 24th biggest holding.
Several other large investors also recently bought and sold shares of JNJ. Aries Wealth Management lifted its stake in shares of Johnson & Johnson by 0.3% during the fourth quarter. Aries Wealth Management now owns 27,932 shares of the company’s stock valued at $4,025,000 after buying an additional 75 shares during the period. Portland Global Advisors LLC boosted its holdings in shares of Johnson & Johnson by 0.9% during the third quarter. Portland Global Advisors LLC now owns 8,744 shares of the company’s stock worth $1,131,000 after purchasing an additional 78 shares during the last quarter. SRS Capital Advisors Inc. grew its position in shares of Johnson & Johnson by 0.5% in the third quarter. SRS Capital Advisors Inc. now owns 17,452 shares of the company’s stock valued at $2,258,000 after purchasing an additional 79 shares during the period. Alta Capital Management LLC grew its position in shares of Johnson & Johnson by 3.9% in the third quarter. Alta Capital Management LLC now owns 2,184 shares of the company’s stock valued at $282,000 after purchasing an additional 82 shares during the period. Finally, G&S Capital LLC grew its position in shares of Johnson & Johnson by 1.8% in the third quarter. G&S Capital LLC now owns 4,668 shares of the company’s stock valued at $604,000 after purchasing an additional 84 shares during the period. 67.28% of the stock is currently owned by institutional investors and hedge funds.
In related news, EVP Kathryn E. Wengel sold 2,017 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $141.07, for a total value of $284,538.19. Following the transaction, the executive vice president now owns 51,736 shares in the company, valued at $7,298,397.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Hubert Joly acquired 5,000 shares of the firm’s stock in a transaction on Friday, December 13th. The shares were acquired at an average price of $141.28 per share, with a total value of $706,400.00. Following the completion of the purchase, the director now owns 5,000 shares of the company’s stock, valued at $706,400. The disclosure for this purchase can be found here. 0.23% of the stock is currently owned by insiders.
Several equities analysts recently weighed in on the company. Zacks Investment Research upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $158.00 target price on the stock in a research report on Wednesday, December 18th. Barclays raised shares of Johnson & Johnson from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $140.00 to $173.00 in a research note on Thursday, December 19th. Atlantic Securities raised shares of Johnson & Johnson from an “underweight” rating to a “neutral” rating in a research note on Wednesday, October 16th. Credit Suisse Group reiterated a “buy” rating and set a $163.00 price objective on shares of Johnson & Johnson in a report on Tuesday, December 31st. Finally, Cantor Fitzgerald started coverage on shares of Johnson & Johnson in a research report on Wednesday, November 27th. They issued an “overweight” rating and a $160.00 target price on the stock. Three analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $159.33.
Shares of Johnson & Johnson stock opened at $147.01 on Thursday. The business’s fifty day moving average price is $143.07 and its 200 day moving average price is $134.77. Johnson & Johnson has a twelve month low of $125.00 and a twelve month high of $147.84. The company has a current ratio of 1.26, a quick ratio of 1.00 and a debt-to-equity ratio of 0.46. The stock has a market capitalization of $385.62 billion, a P/E ratio of 16.71, a PEG ratio of 2.36 and a beta of 0.71.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 15th. The company reported $2.12 EPS for the quarter, topping analysts’ consensus estimates of $2.00 by $0.12. Johnson & Johnson had a return on equity of 39.81% and a net margin of 21.09%. The company had revenue of $20.73 billion for the quarter, compared to the consensus estimate of $20.14 billion. During the same period last year, the business posted $2.05 EPS. The company’s quarterly revenue was up 1.9% compared to the same quarter last year. As a group, sell-side analysts predict that Johnson & Johnson will post 8.66 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 25th will be issued a dividend of $0.95 per share. This represents a $3.80 dividend on an annualized basis and a dividend yield of 2.58%. The ex-dividend date is Monday, February 24th. Johnson & Johnson’s payout ratio is currently 46.45%.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Further Reading: Diversification in Your Portfolio
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.